GSK: drug reduces exacerbations in COPD.
(CercleFinance.com) - Patients suffering from a difficult-to-treat form of chronic obstructive pulmonary disease (COPD) were less likely to experience exacerbations when using GSK's mepolizumab, the British drugmaker said on Tuesday.
Overall, COPD patients with high blood eosinophil counts and treated with mepolizumab showed a consistent 18-20% reduction in the primary endpoint of annual rate of moderate and severe exacerbations, GSK said.
Based on this phase III data, the firm plans a regulatory filings for 2017.
Mepolizumab is not approved for use anywhere in the world for COPD.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
Overall, COPD patients with high blood eosinophil counts and treated with mepolizumab showed a consistent 18-20% reduction in the primary endpoint of annual rate of moderate and severe exacerbations, GSK said.
Based on this phase III data, the firm plans a regulatory filings for 2017.
Mepolizumab is not approved for use anywhere in the world for COPD.
Copyright (c) 2017 CercleFinance.com. All rights reserved.